Evaluation of Probiotics' Effect on Atrial Fibrillation Recurrence in Patients Undergoing Cardioversion

Effect of Probiotics on Atrial Fibrillation Outcome in Patients Undergoing Cardioversion

The aim of this clinical study is to evaluate the efficacy and tolerability of probiotics on atrial fibrillation recurrence.

Assessment of AF recurrence: Early AF recurrence is defined as relapse into AF within 1 week following successful cardioversion and AF recurrence through the study's 12-week follow-up.

Patients and Methods Design: Prospective, randomized, open label, controlled clinical trial

Patients: A total of 56 AF patients undergoing cardioversion will be randomly enrolled into one of 2 arms:

1. Group 1 (Control group) (n=28): AF patients undergoing cardioversion who will receive the standard of care
2. Group 2 (Probiotic group) (n = 28): AF patients undergoing cardioversion who will receive the standard of care in addition to probiotics DAILY orally administered (Probiotics 25 billion) after cardioversion for 12 weeks.

Groups (1 & 2) will be subjected to cardioversion on admission according to standard protocols and criteria.

Inclusion Criteria:

1. Female or male aged 40 years or above with BMI less than 40
2. Persistent AF patients directly after cardioversion

Exclusion Criteria:

1. History of probiotic supplementation in the previous 6 weeks
2. Autoimmune diseases
3. Ongoing treatment with immunosuppressive therapies
4. Active Infection
5. Pregnant or breast-feeding patients
6. Active participation in another clinical study
7. History of or known allergy or intolerability to the study medications